CN102177156A - 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 - Google Patents
制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 Download PDFInfo
- Publication number
- CN102177156A CN102177156A CN2009801401444A CN200980140144A CN102177156A CN 102177156 A CN102177156 A CN 102177156A CN 2009801401444 A CN2009801401444 A CN 2009801401444A CN 200980140144 A CN200980140144 A CN 200980140144A CN 102177156 A CN102177156 A CN 102177156A
- Authority
- CN
- China
- Prior art keywords
- described method
- group
- following formula
- compound
- formula structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(CO*)(CN1c(cc2C*)cc(*)c2-c2cnc(*)cc2)OC1=O Chemical compound CC(CO*)(CN1c(cc2C*)cc(*)c2-c2cnc(*)cc2)OC1=O 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Abstract
Description
时间(min) | 流速(mL/min) | %A | %B |
0.0 | 1.0 | 98.0 | 2.0 |
15.0 | 1.0 | 5.0 | 95.0 |
25.0 | 1.0 | 5.0 | 95.0 |
27.0 | 1.0 | 98.0 | 2.0 |
30.0 | 1.0 | 98.0 | 2.0 |
1.时间(min) | 2.流速(mL/min) | %A | %B |
0.0 | 1.0 | 98.0 | 2.0 |
15.0 | 1.0 | 5.0 | 95.0 |
25.0 | 1.0 | 5.0 | 95.0 |
27.0 | 1.0 | 98.0 | 2.0 |
30.0 | 1.0 | 98.0 | 2.0 |
3.时间(min) | 4.流速(mL/min) | %A | %B |
0.0 | 1.0 | 98.0 | 2.0 |
15.0 | 1.0 | 5.0 | 95.0 |
25.0 | 1.0 | 5.0 | 95.0 |
27.0 | 1.0 | 98.0 | 2.0 |
30.0 | 1.0 | 98.0 | 2.0 |
试验 | 结果 |
外观 | 白色或类白色 |
1HNMR | 一致 |
31PNMR | 一致 |
保留时间 | 5.18分钟 |
MS | m/z371 |
HPLC纯度 | 99.6* |
HPLC杂质 | 二聚体,0.09%* |
铜含量 | <1ppm |
钯含量 | 1ppm |
钠含量 | 8.34% |
水含量 | 5.5% |
旋光度 | -34.9° |
XRPD | 非晶体 |
粒度 | 1-300μm |
Claims (37)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610581761.XA CN106220621B (zh) | 2008-10-10 | 2009-10-09 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10446908P | 2008-10-10 | 2008-10-10 | |
US61/104,469 | 2008-10-10 | ||
PCT/US2009/060267 WO2010042887A2 (en) | 2008-10-10 | 2009-10-09 | Methods for preparing oxazolidinones and compositions containing them |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610581761.XA Division CN106220621B (zh) | 2008-10-10 | 2009-10-09 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102177156A true CN102177156A (zh) | 2011-09-07 |
CN102177156B CN102177156B (zh) | 2016-08-24 |
Family
ID=41382395
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610581761.XA Active CN106220621B (zh) | 2008-10-10 | 2009-10-09 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
CN200980140144.4A Active CN102177156B (zh) | 2008-10-10 | 2009-10-09 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610581761.XA Active CN106220621B (zh) | 2008-10-10 | 2009-10-09 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
Country Status (13)
Country | Link |
---|---|
US (2) | US8604209B2 (zh) |
EP (2) | EP2757104B1 (zh) |
JP (1) | JP5773875B2 (zh) |
KR (1) | KR101674146B1 (zh) |
CN (2) | CN106220621B (zh) |
AU (1) | AU2009303301B2 (zh) |
CA (1) | CA2738671C (zh) |
ES (2) | ES2748505T3 (zh) |
HK (2) | HK1200169A1 (zh) |
MX (2) | MX366793B (zh) |
RU (2) | RU2556234C2 (zh) |
SG (2) | SG10201702946RA (zh) |
WO (1) | WO2010042887A2 (zh) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104327119A (zh) * | 2014-10-17 | 2015-02-04 | 苏州明锐医药科技有限公司 | 磷酸泰地唑胺的制备方法 |
CN104496979A (zh) * | 2014-09-17 | 2015-04-08 | 博瑞生物医药技术(苏州)有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
CN104558034A (zh) * | 2015-01-21 | 2015-04-29 | 齐鲁制药有限公司 | 磷酸特地唑胺二钠盐的新晶型及其制备方法 |
CN104592218A (zh) * | 2015-02-13 | 2015-05-06 | 江苏欧信医药化工有限公司 | 一种泰地唑胺的合成方法 |
CN104892592A (zh) * | 2015-03-30 | 2015-09-09 | 成都惟新医药科技有限公司 | 一种泰地唑胺的制备方法 |
CN105131037A (zh) * | 2015-07-28 | 2015-12-09 | 济南爱思医药科技有限公司 | 一种高纯度泰地唑胺磷酸酯的制备方法 |
CN105367547A (zh) * | 2014-08-19 | 2016-03-02 | 蔡苹 | 一种噁唑啉酮抗生素的新合成工艺 |
CN105418681A (zh) * | 2015-12-15 | 2016-03-23 | 南京艾德凯腾生物医药有限责任公司 | 一种磷酸特地唑胺的制备方法 |
CN105837634A (zh) * | 2015-01-30 | 2016-08-10 | 上海创诺制药有限公司 | 一种泰地唑胺磷酸酯结晶体及其制备方法 |
CN106146560A (zh) * | 2016-07-12 | 2016-11-23 | 扬子江药业集团有限公司 | 一种高纯度磷酸特地唑胺的精制方法 |
CN106146485A (zh) * | 2015-04-01 | 2016-11-23 | 上海创诺医药集团有限公司 | 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体 |
CN106279282A (zh) * | 2015-05-21 | 2017-01-04 | 博瑞生物医药(苏州)股份有限公司 | 一种磷酸特地唑胺的纯化方法 |
CN106279281A (zh) * | 2015-05-15 | 2017-01-04 | 重庆圣华曦药业股份有限公司 | 噁唑烷酮类抗菌素泰地唑胺磷酸酯的精制方法 |
CN106317114A (zh) * | 2015-07-02 | 2017-01-11 | 南京优科制药有限公司 | 一种磷酸特地唑胺的制备方法 |
CN106432182A (zh) * | 2016-09-06 | 2017-02-22 | 铜仁学院 | 特地唑胺中间体的合成方法 |
CN106565680A (zh) * | 2016-10-31 | 2017-04-19 | 瑞阳制药有限公司 | 特地唑胺杂质及其制备方法 |
CN106632298A (zh) * | 2015-11-03 | 2017-05-10 | 上海科胜药物研发有限公司 | 一种泰地唑胺的制备方法及其中间体 |
CN106632240A (zh) * | 2016-11-25 | 2017-05-10 | 山东轩德医药科技有限公司 | 一种2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法 |
CN106699730A (zh) * | 2016-12-23 | 2017-05-24 | 山东轩德医药科技有限公司 | 2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法 |
CN107488188A (zh) * | 2016-06-12 | 2017-12-19 | 重庆圣华曦药业股份有限公司 | 一种制备特地唑胺关键中间体的新合成方法 |
CN108059624A (zh) * | 2016-11-08 | 2018-05-22 | 上海医药工业研究院 | 用于制备咔哒唑胺关键中间体的制备方法 |
CN110804038A (zh) * | 2018-08-06 | 2020-02-18 | 上海博志研新药物技术有限公司 | 磷酸特地唑胺及其中间体的制备方法 |
CN110938058A (zh) * | 2018-09-22 | 2020-03-31 | 南京优科生物医药研究有限公司 | 一种噁唑烷酮类抗生素中间体的制备方法 |
CN111285848A (zh) * | 2020-04-10 | 2020-06-16 | 苏州敬业医药化工有限公司 | 一种5-溴-2-(2-甲基-2h-四唑-5-基)吡啶的纯化方法 |
CN112961186A (zh) * | 2021-02-04 | 2021-06-15 | 海南通用康力制药有限公司 | 一种磷酸特地唑胺的纯化方法 |
CN113121518A (zh) * | 2019-12-31 | 2021-07-16 | 北京福元医药股份有限公司 | 一种特地唑胺杂质的制备方法 |
CN113248471A (zh) * | 2021-07-05 | 2021-08-13 | 南京桦冠生物技术有限公司 | 一种唑胺类药物中间体的制备方法及其中间体 |
CN114105946A (zh) * | 2020-08-26 | 2022-03-01 | 浙江苏泊尔制药有限公司 | 一种磷酸特地唑胺中间体及其制备方法 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
EP2757104B1 (en) * | 2008-10-10 | 2019-08-14 | Merck Sharp & Dohme Corp. | Compounds used in the synthesis of oxazolidinones |
CU24089B1 (es) | 2009-02-03 | 2015-04-29 | Trius Therapeutics | Forma cristalina del fosfato de dihidrógeno r)-3-(4-(2-(2-metiltretazol-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona |
US8580767B2 (en) * | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
WO2012033952A1 (en) | 2010-09-10 | 2012-03-15 | Micurx Pharmaceuticals, Inc. | 3 - phenyl- 2 -oxo- 1, 3 -oxazolidines for treatment of bacterial infections |
WO2016009401A2 (en) * | 2014-07-18 | 2016-01-21 | Dr. Reddy's Laboratories Limited | Preparation of tedizolid phosphate |
WO2016041505A1 (zh) * | 2014-09-17 | 2016-03-24 | 正大天晴药业集团股份有限公司 | 一种磷酸特地唑胺、其中间体以及它们的制备方法 |
WO2016088103A1 (en) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | A process for the preparation of tedizolid phosphate |
WO2016088100A1 (en) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Processes for the preparation of tedizolid phosphate and its intermediates |
WO2016088102A1 (en) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Processes for the preparation of tedizolid phosphate and its intermediates |
WO2016088101A1 (en) * | 2014-12-05 | 2016-06-09 | Sun Pharmaceutical Industries Limited | Processes for the preparation of tedizolid phosphate and its intermediates |
KR101855334B1 (ko) * | 2015-12-11 | 2018-06-08 | 에스티팜 주식회사 | 옥사졸리디논 유도체의 중간체 제조방법 |
CN107722056A (zh) * | 2017-10-31 | 2018-02-23 | 重庆华邦胜凯制药有限公司 | 磷酸特地唑胺的制备方法 |
WO2019118311A1 (en) | 2017-12-13 | 2019-06-20 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of tedizolid phosphate |
CN111116652A (zh) * | 2019-12-06 | 2020-05-08 | 山东中医药大学 | 一种高纯度磷酸特地唑胺的制备方法 |
CA3183397A1 (en) | 2020-06-18 | 2021-12-23 | Daryl C. Drummond | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof |
CN113488445A (zh) * | 2021-07-05 | 2021-10-08 | 合肥巨一动力系统有限公司 | 一种igbt封装散热结构及其应用的电机控制器 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU80081A1 (fr) * | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
US4128654A (en) * | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4340606A (en) | 1980-10-23 | 1982-07-20 | E. I. Du Pont De Nemours And Company | 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents |
FR2500450A1 (fr) * | 1981-02-25 | 1982-08-27 | Delalande Sa | Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique |
US4461773A (en) * | 1982-09-15 | 1984-07-24 | E. I. Dupont De Nemours And Company | P-Oxooxazolidinylbenzene compounds as antibacterial agents |
CA1320730C (en) | 1987-10-16 | 1993-07-27 | The Du Pont Merck Pharmaceutical Company | Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents |
US4948801A (en) * | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
WO1993009103A1 (en) * | 1991-11-01 | 1993-05-13 | The Upjohn Company | Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents |
SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
CA2147753C (en) * | 1992-12-08 | 2004-08-03 | Michael Robert Barbachyn | Tropone-substituted phenyloxazolidinone antibacterial agents |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
AU698699B2 (en) | 1993-11-22 | 1998-11-05 | Pharmacia & Upjohn Company | Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones |
GB9702213D0 (en) * | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
US6413981B1 (en) * | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
GB0009803D0 (en) * | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
AU5889701A (en) | 2000-06-05 | 2001-12-17 | Dong A Pharm Co Ltd | Novel oxazolidinone derivatives and a process for the preparation thereof |
US20020115669A1 (en) * | 2000-08-31 | 2002-08-22 | Wiedeman Paul E. | Oxazolidinone chemotherapeutic agents |
ES2268011T3 (es) | 2001-04-07 | 2007-03-16 | Astrazeneca Ab | Oxazolidinonas que contienen un grupo sulfonimida como antibioticos. |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
SI1427711T1 (sl) * | 2001-09-11 | 2005-12-31 | Astrazeneca Ab | Oksazolidinonski in/ali izoksazolinski derivati kot antibakterijska sredstva |
US20050043374A1 (en) | 2001-10-25 | 2005-02-24 | Gravestock Michael Barry | Aryl substituted oxazolidinones with antibacterial activity |
NZ515881A (en) | 2001-12-03 | 2004-09-24 | New Zealand Dairy Board | Cheese flavour ingredient and method of its production |
PL372191A1 (en) * | 2002-02-28 | 2005-07-11 | Astrazeneca Ab | 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents |
BR0308018A (pt) | 2002-02-28 | 2005-01-04 | Astrazeneca Ab | Composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo, pró-droga, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hirolisável in vivo, composição farmacêutica, e, processo para a preparação de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
US7498350B2 (en) * | 2002-11-28 | 2009-03-03 | Astrazeneca Ab | Oxazolidinones as antibacterial agents |
WO2004048392A1 (en) * | 2002-11-28 | 2004-06-10 | Astrazeneca Ab | Oxazolidinone and / or isoxazoline derivatives as antibacterial agents |
GB0229518D0 (en) * | 2002-12-19 | 2003-01-22 | Astrazeneca Ab | Chemical compounds |
US7144911B2 (en) * | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7202257B2 (en) * | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
TW200500360A (en) * | 2003-03-01 | 2005-01-01 | Astrazeneca Ab | Hydroxymethyl compounds |
GB0306358D0 (en) * | 2003-03-20 | 2003-04-23 | Astrazeneca Ab | Chemical compounds |
JP2007521283A (ja) * | 2003-07-02 | 2007-08-02 | メルク アンド カンパニー インコーポレーテッド | シクロプロピル基で置換されたオキサゾリジノン系抗生物質およびその誘導体 |
JP4607107B2 (ja) * | 2003-07-02 | 2011-01-05 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピル基置換されたオキサゾリジノン抗生物質およびこれらの誘導体 |
WO2005051933A1 (en) | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby |
TW200526649A (en) * | 2003-12-17 | 2005-08-16 | Rib X Pharmaceuticals Inc | Halogenated biaryl heterocyclic compounds and methods of making and using the same |
KR100854211B1 (ko) * | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
US20070191336A1 (en) * | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
US20080064689A1 (en) | 2004-05-25 | 2008-03-13 | Astrazeneca Ab | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents |
US20080021071A1 (en) | 2004-05-25 | 2008-01-24 | Astrazeneca Ab | 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents |
EP1753753A1 (en) * | 2004-05-25 | 2007-02-21 | AstraZeneca AB | 3-(4-(2-dihydroisoxazol-3-ylpyrdin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections |
GB0411596D0 (en) | 2004-05-25 | 2004-06-30 | Astrazeneca Ab | Chemical process |
CA2566963A1 (en) * | 2004-05-25 | 2005-12-08 | Astrazeneca Ab | 3-[4-{6-substituted alkanoyl pyridin-3-yl}-3-phenyl]-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents |
US20100286211A1 (en) | 2004-10-08 | 2010-11-11 | Biswajit Das | Oxazolidinone derivatives as antimicrobials |
US20090018123A1 (en) | 2005-06-20 | 2009-01-15 | Milind D Sindkhedkar | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation |
WO2007138381A2 (en) | 2005-10-14 | 2007-12-06 | Targanta Therapeutics Inc. | Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections |
CN101720325B (zh) | 2007-08-06 | 2013-04-24 | 上海盟科药业有限公司 | 用于治疗细菌感染的抗菌邻-氟苯基噁唑烷酮 |
EP2757104B1 (en) | 2008-10-10 | 2019-08-14 | Merck Sharp & Dohme Corp. | Compounds used in the synthesis of oxazolidinones |
CU24089B1 (es) | 2009-02-03 | 2015-04-29 | Trius Therapeutics | Forma cristalina del fosfato de dihidrógeno r)-3-(4-(2-(2-metiltretazol-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona |
US8580767B2 (en) | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
-
2009
- 2009-10-09 EP EP14159112.3A patent/EP2757104B1/en active Active
- 2009-10-09 CN CN201610581761.XA patent/CN106220621B/zh active Active
- 2009-10-09 SG SG10201702946RA patent/SG10201702946RA/en unknown
- 2009-10-09 WO PCT/US2009/060267 patent/WO2010042887A2/en active Application Filing
- 2009-10-09 ES ES09749235T patent/ES2748505T3/es active Active
- 2009-10-09 RU RU2011115109/04A patent/RU2556234C2/ru active
- 2009-10-09 AU AU2009303301A patent/AU2009303301B2/en active Active
- 2009-10-09 KR KR1020117010217A patent/KR101674146B1/ko active IP Right Grant
- 2009-10-09 CN CN200980140144.4A patent/CN102177156B/zh active Active
- 2009-10-09 CA CA2738671A patent/CA2738671C/en active Active
- 2009-10-09 MX MX2014004600A patent/MX366793B/es unknown
- 2009-10-09 RU RU2015122033A patent/RU2659792C1/ru active
- 2009-10-09 US US12/577,089 patent/US8604209B2/en active Active
- 2009-10-09 ES ES14159112T patent/ES2744907T3/es active Active
- 2009-10-09 JP JP2011531233A patent/JP5773875B2/ja active Active
- 2009-10-09 MX MX2011003820A patent/MX2011003820A/es active IP Right Grant
- 2009-10-09 EP EP09749235.9A patent/EP2346858B1/en active Active
- 2009-10-09 SG SG2013075965A patent/SG195544A1/en unknown
-
2013
- 2013-11-25 US US14/089,050 patent/US9328087B2/en active Active
-
2015
- 2015-01-19 HK HK15100600.5A patent/HK1200169A1/zh unknown
-
2017
- 2017-06-13 HK HK17105843.9A patent/HK1232221A1/zh unknown
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105367547A (zh) * | 2014-08-19 | 2016-03-02 | 蔡苹 | 一种噁唑啉酮抗生素的新合成工艺 |
CN105367547B (zh) * | 2014-08-19 | 2019-04-23 | 北京桦冠生物技术有限公司 | 一种噁唑啉酮抗生素的新合成工艺 |
CN106928214A (zh) * | 2014-09-17 | 2017-07-07 | 博瑞生物医药(苏州)股份有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
CN104496979A (zh) * | 2014-09-17 | 2015-04-08 | 博瑞生物医药技术(苏州)有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
WO2016041508A1 (zh) * | 2014-09-17 | 2016-03-24 | 博瑞生物医药技术(苏州)有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
CN104327119A (zh) * | 2014-10-17 | 2015-02-04 | 苏州明锐医药科技有限公司 | 磷酸泰地唑胺的制备方法 |
CN104558034A (zh) * | 2015-01-21 | 2015-04-29 | 齐鲁制药有限公司 | 磷酸特地唑胺二钠盐的新晶型及其制备方法 |
CN105837634A (zh) * | 2015-01-30 | 2016-08-10 | 上海创诺制药有限公司 | 一种泰地唑胺磷酸酯结晶体及其制备方法 |
CN104592218B (zh) * | 2015-02-13 | 2015-11-04 | 江苏欧信医药化工有限公司 | 一种泰地唑胺的合成方法 |
CN104592218A (zh) * | 2015-02-13 | 2015-05-06 | 江苏欧信医药化工有限公司 | 一种泰地唑胺的合成方法 |
CN104892592A (zh) * | 2015-03-30 | 2015-09-09 | 成都惟新医药科技有限公司 | 一种泰地唑胺的制备方法 |
CN106146485B (zh) * | 2015-04-01 | 2021-04-30 | 上海迪赛诺化学制药有限公司 | 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体 |
CN106146485A (zh) * | 2015-04-01 | 2016-11-23 | 上海创诺医药集团有限公司 | 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体 |
CN106279281B (zh) * | 2015-05-15 | 2018-08-03 | 重庆圣华曦药业股份有限公司 | 噁唑烷酮类抗菌素泰地唑胺磷酸酯的精制方法 |
CN106279281A (zh) * | 2015-05-15 | 2017-01-04 | 重庆圣华曦药业股份有限公司 | 噁唑烷酮类抗菌素泰地唑胺磷酸酯的精制方法 |
CN106279282A (zh) * | 2015-05-21 | 2017-01-04 | 博瑞生物医药(苏州)股份有限公司 | 一种磷酸特地唑胺的纯化方法 |
CN106279282B (zh) * | 2015-05-21 | 2019-08-23 | 博瑞生物医药(苏州)股份有限公司 | 一种磷酸特地唑胺的纯化方法 |
CN106317114A (zh) * | 2015-07-02 | 2017-01-11 | 南京优科制药有限公司 | 一种磷酸特地唑胺的制备方法 |
CN105131037A (zh) * | 2015-07-28 | 2015-12-09 | 济南爱思医药科技有限公司 | 一种高纯度泰地唑胺磷酸酯的制备方法 |
CN108368100A (zh) * | 2015-11-03 | 2018-08-03 | 浙江华海药业股份有限公司 | 一种泰地唑胺的制备方法及其中间体和制备方法 |
CN106632298A (zh) * | 2015-11-03 | 2017-05-10 | 上海科胜药物研发有限公司 | 一种泰地唑胺的制备方法及其中间体 |
CN106632298B (zh) * | 2015-11-03 | 2021-06-01 | 上海科胜药物研发有限公司 | 一种泰地唑胺的制备方法及其中间体 |
CN108368100B (zh) * | 2015-11-03 | 2021-07-23 | 浙江华海药业股份有限公司 | 一种泰地唑胺的制备方法及其中间体和制备方法 |
CN105418681A (zh) * | 2015-12-15 | 2016-03-23 | 南京艾德凯腾生物医药有限责任公司 | 一种磷酸特地唑胺的制备方法 |
CN107488188A (zh) * | 2016-06-12 | 2017-12-19 | 重庆圣华曦药业股份有限公司 | 一种制备特地唑胺关键中间体的新合成方法 |
CN106146560A (zh) * | 2016-07-12 | 2016-11-23 | 扬子江药业集团有限公司 | 一种高纯度磷酸特地唑胺的精制方法 |
CN106432182A (zh) * | 2016-09-06 | 2017-02-22 | 铜仁学院 | 特地唑胺中间体的合成方法 |
CN106432182B (zh) * | 2016-09-06 | 2019-04-30 | 铜仁学院 | 特地唑胺中间体的合成方法 |
CN106565680A (zh) * | 2016-10-31 | 2017-04-19 | 瑞阳制药有限公司 | 特地唑胺杂质及其制备方法 |
CN108059624A (zh) * | 2016-11-08 | 2018-05-22 | 上海医药工业研究院 | 用于制备咔哒唑胺关键中间体的制备方法 |
CN106632240A (zh) * | 2016-11-25 | 2017-05-10 | 山东轩德医药科技有限公司 | 一种2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法 |
CN106699730A (zh) * | 2016-12-23 | 2017-05-24 | 山东轩德医药科技有限公司 | 2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法 |
CN110804038B (zh) * | 2018-08-06 | 2021-03-05 | 上海博志研新药物技术有限公司 | 磷酸特地唑胺及其中间体的制备方法 |
CN110804038A (zh) * | 2018-08-06 | 2020-02-18 | 上海博志研新药物技术有限公司 | 磷酸特地唑胺及其中间体的制备方法 |
CN110938058A (zh) * | 2018-09-22 | 2020-03-31 | 南京优科生物医药研究有限公司 | 一种噁唑烷酮类抗生素中间体的制备方法 |
CN110938058B (zh) * | 2018-09-22 | 2022-04-12 | 南京优科生物医药研究有限公司 | 一种噁唑烷酮类抗生素中间体的制备方法 |
CN113121518A (zh) * | 2019-12-31 | 2021-07-16 | 北京福元医药股份有限公司 | 一种特地唑胺杂质的制备方法 |
CN113121518B (zh) * | 2019-12-31 | 2022-06-28 | 北京福元医药股份有限公司 | 一种特地唑胺杂质的制备方法 |
CN111285848A (zh) * | 2020-04-10 | 2020-06-16 | 苏州敬业医药化工有限公司 | 一种5-溴-2-(2-甲基-2h-四唑-5-基)吡啶的纯化方法 |
CN114105946A (zh) * | 2020-08-26 | 2022-03-01 | 浙江苏泊尔制药有限公司 | 一种磷酸特地唑胺中间体及其制备方法 |
CN112961186A (zh) * | 2021-02-04 | 2021-06-15 | 海南通用康力制药有限公司 | 一种磷酸特地唑胺的纯化方法 |
CN113248471A (zh) * | 2021-07-05 | 2021-08-13 | 南京桦冠生物技术有限公司 | 一种唑胺类药物中间体的制备方法及其中间体 |
CN113248471B (zh) * | 2021-07-05 | 2021-09-21 | 南京桦冠生物技术有限公司 | 一种唑胺类药物中间体的制备方法及其中间体 |
Also Published As
Publication number | Publication date |
---|---|
US20100093669A1 (en) | 2010-04-15 |
ES2744907T3 (es) | 2020-02-26 |
MX366793B (es) | 2019-07-24 |
US20140206878A1 (en) | 2014-07-24 |
RU2556234C2 (ru) | 2015-07-10 |
ES2748505T3 (es) | 2020-03-17 |
CA2738671C (en) | 2018-05-01 |
AU2009303301B2 (en) | 2014-09-11 |
HK1232221A1 (zh) | 2018-01-05 |
JP2012505252A (ja) | 2012-03-01 |
WO2010042887A3 (en) | 2010-06-24 |
JP5773875B2 (ja) | 2015-09-02 |
HK1200169A1 (zh) | 2015-07-31 |
CN106220621B (zh) | 2019-06-11 |
SG195544A1 (en) | 2013-12-30 |
EP2346858A2 (en) | 2011-07-27 |
AU2009303301A1 (en) | 2010-04-15 |
EP2346858B1 (en) | 2019-08-07 |
CN106220621A (zh) | 2016-12-14 |
WO2010042887A2 (en) | 2010-04-15 |
SG10201702946RA (en) | 2017-05-30 |
US9328087B2 (en) | 2016-05-03 |
RU2011115109A (ru) | 2012-11-20 |
EP2757104A1 (en) | 2014-07-23 |
KR101674146B1 (ko) | 2016-11-08 |
CN102177156B (zh) | 2016-08-24 |
MX2011003820A (es) | 2011-06-16 |
EP2757104B1 (en) | 2019-08-14 |
US8604209B2 (en) | 2013-12-10 |
KR20110071107A (ko) | 2011-06-28 |
RU2659792C1 (ru) | 2018-07-04 |
CA2738671A1 (en) | 2010-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102177156A (zh) | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 | |
KR102108864B1 (ko) | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 | |
AU2007269557B2 (en) | Modulators of toll-like receptor 7 | |
WO2016041877A1 (en) | Methods for the preparation of diastereomerically pure phosphoramidate prodrugs | |
AU617724B2 (en) | 9-(2-(Phosphonomethoxy)Ethoxy) Purine derivatives, intermediates and use as pharmaceuticals | |
Hocek et al. | Synthesis of acyclic nucleotide analogues derived from N-substituted 6-(1-aminoethyl) purines via 6-acetylpurine derivatives | |
KR900002709B1 (ko) | 푸린-9-일알킬렌옥시메틸 포스폰산의 합성방법 | |
Lu et al. | Stereoselective Synthesis of Phosphorothioate and Alkylphosphinate Analogs Using a l-Tryptophan Derived Chiral Auxiliary | |
Davidowitz, Bette* & Modro | Phosphoric amides: part 6: 1 intramolecular nucleophilic displacement in?-haloethyl-substituted phosphoramidates | |
OA16292A (en) | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs. | |
Mikołajczyk et al. | Stereochemistry of organophosphorus cylic compounds—XV: Synthesis of tetramethylammonium salt of 2-oxo-2-thio-1, 3, 2,-oxazaphosphorinan and its crystal and molecular structures | |
SE1451080A1 (sv) | Medivir AB, Box 1086, 141 22 Huddinge, SE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB02 | Change of applicant information |
Address after: Massachusetts, USA Applicant after: TRIUS THERAPEUTICS Address before: California, USA Applicant before: Trius Therapeutics |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160314 Address after: New jersey, USA Applicant after: MERCK SHARP & DOHME Corp. Address before: Massachusetts, USA Applicant before: Trius Therapeutics |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230105 Address after: new jersey Patentee after: MERCK SHARP & DOHME B.V. Address before: new jersey Patentee before: MERCK SHARP & DOHME Corp. |
|
TR01 | Transfer of patent right |